Treato Appoints Gregory A. Gallo As New Chief Commercial Officer

Healthcare Industry Leader Joins Company To Expand Professional Services Business

Feb 10, 2016, 09:14 ET from Treato

OR YEHUDA, Israel and PRINCETON, New Jersey, February 10, 2016 /PRNewswire/ --

Today Treato, the single largest source of online consumer insights on healthcare, announced the appointment of Greg Gallo as the company's new Chief Commercial Officer. In this role Greg will lead and expand the company's business solutions unit, which now partners with nine out of the world's top 10 pharma companies.

"We are excited to have Greg join our leadership team and look forward to benefitting from his vast knowledge and commercial experience in the healthcare data and analytics field," said Ido Hadari, CEO of Treato.  "Greg has a remarkable track record in helping build, lead and scale innovative businesses. At Treato, he will lead our business solutions offerings and continue to expand our position as the go-to source for pharmaceutical companies to access insights from real-world experiences by real people that drive market share optimization and improved patient outcomes."

Greg joins most recently from Activate Networks, acquired by Decision Resources Group in 2015, where as their Chief Commercial Officer he was responsible for the commercial operations and growth.  He has more than 20 years of commercial experience, including senior roles at Quest Diagnostics, ImpactRx and Johnson & Johnson.

About Treato: 

Treato™, the leading source of health insights from millions of real health consumers, uses patented analytics and big data technology to turn billions of disparate online conversations into meaningful social intelligence. With more than two billion posts analyzed and continuously expanding, Treato has partnered with nine out of the world's top 10 pharma companies as well as numerous other multi-national pharmaceutical companies and healthcare organizations., its consumer website, helps millions of visitors each month.

Treato is privately held with offices in Israel, New York and Princeton, NJ. Investors include Reed Elsevier Ventures, OrbiMed Partners and New Leaf Venture Partners, among others. For more information please visit